Genmab — December 2014
-
Der var intet nyt om arzerra i weekenden celsius. Men en masse daranyt. Så nok derfor
-
der var en præsentation i fredags og der komemr en præsentation fra det fejlede DLBLC studie i dag. Men ikke noget gennemgribende nyt i det som kom. SÅ mere en bekræftelse af det vi allerede ved, nemlig at Arzerra får det meget svært fremover
-
OMFG !
-
Aktiekursen

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind